drugset / Trial / NCT00286806
A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is an open-label, multicenter Phase I/II study to evaluate the safety and efficacy of single-agent AT-101 in men with hormone-refractory prostate cancer.
Timeline
- Start
- 2005-12
- Primary completion
- 2007-06
- Completion
- 2007-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AT-101 | Small molecule | — | — |